Endovascular treatment of cerebral vasospasm with milrinone and nimodipine

Repeated combined endovascular therapy with milrinone and nimodipine for the treatment of severe cerebral vasospasm

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN36126862

Enrollment

Registered

2018-11-21

Start date

2013-01-01

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe cerebral vasospasm Circulatory System Severe cerebral vasospasm as a complication of aneurysmal subarachnoidal haemorrhage, leading to delayed ischemic neurological deficits

Interventions

All patients received endovascular therapy with 2 mg nimodipine infused over 20 minutes, followed by 5 mg milrinone infused over 30 minutes into the symptomatic vessels using an angiography catheter p

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aneurysmal subarachnoid haemorrhage 2. Consecutive cerebral vasospasm 3. Treated in Krankenanstalt Rudolfstiftung during the observational period 4. Aged 18-85 years

Exclusion criteria

Exclusion criteria: Not meeting the participant inclusion criteria

Design outcomes

Primary

Measure	Time frame
Clinical outcome, assessed at the baseline, on the day of discharge and at least 6 weeks after, using the following: 1. Glasgow Outcome Score (GOS) 2. Modified Ranking Scale (mRS)	—

Secondary

Measure	Time frame
The following are assessed at the baseline, on the day of discharge and after 6 weeks: 1. Vessel diameter, assessed using the Centricity Universal Viewer through digital subtraction of the angiogram pre- and post-intervention 2. Transcranial Doppler (TCD) values, assessed using a standard transcranial Doppler sonography set	—

Countries

Austria

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026